Trends & Analysis

#Artificial intelligence (AI) #Clinical trial design #Clinical trials #Machine learning

AI and machine learning: A new era for clinical trials

Fiona Maini, Senior Director Global Compliance & Strategy, at Medidata looks at the rise of artificial intelligence (AI) and machine learning (ML) within life sciences and the applications for the technology in clinical trials. The benefits that AI and machine learning (ML) can bring to society and their potential to… Read More

#Exclusive Content #Trends & Analysis

2024 predictions, road forward
#2024 predictions #BioSenic #Cytiva #Monoclonal antibodies #Sphere Fluidics #TrakCel

2024 predictions: Experts comment on monoclonal antibodies 

DDW’s Megan Thomas speaks to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. This is part of a series of predictions based on different themes. Here, experts weigh in on the future of monoclonal antibodies (mAbs).  Amanda Halford, President… Read More

#Exclusive Content #Trends & Analysis

Someone using a keyboard
#AI / data analytics / healthtech / informatics #Data management #Informatics #Market reporting

Drug discovery informatics market predicted to grow 12.6% by 2028

The drug discovery informatics market is predicted to grow from $3.77 billion in 2024 to $6.06 billion in 2028 at a compound annual growth rate (CAGR) of 12.6%, according to analysts ResearchAndMarkets.com. The recent growth in the market is attributed to advancements in genomics and proteomics,… Read More

#Business & Investment #Market Reports #News #Trends & Analysis

Drug discovery technology
#2024 predictions #Antibody drug conjugate (ADC) #Artificial intelligence (AI) #Gene therapy

Key drug development trends and predictions for 2024

Dr Julie Warner is Vice President of Regulatory Affairs at drug development consultancy, Boyds. In this article, she provides her expert insights into the key trends and developments expected to shape the global drug development industry this year. Financial landscape In 2023, life science companies experienced… Read More

#Exclusive Content #Trends & Analysis

2024 predictions, road forward
#2024 predictions #AI / data analytics / healthtech / informatics #Antiverse #Artificial intelligence (AI) #Drug discovery #Elsevier #Enhanc3D Genomics #IQVIA #Lab automation #Machine learning #Medidata #Ori Biotech #Technology #TrakCel #Trinity Life Sciences

2024 predictions: Experts comment on AI, ML and automation

DDW’s Megan Thomas spoke to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. This is part of a series of predictions based on different themes. Here, experts weigh in on the impact of artificial intelligence (AI), machine learning (ML) and automation in… Read More

#Exclusive Content #Opinion #Trends & Analysis

2024 predictions, road forward
#2024 predictions #AstraZeneca #BioSenic #Cancer #Drug discovery #Mosaic Therapeutics #Oncology #OrganaBio #Phesi #Therapeutics

2024 predictions: Experts weigh in on cancer research

DDW’s Megan Thomas spoke to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. This is part of a series of predictions based on different themes. Here, experts weigh in on what to expect from cancer research and immunotherapies. Greg Rossi, Senior Vice… Read More

#Cancer Research #Exclusive Content #Opinion #Trends & Analysis

#Biopharmaceuticals #Clarivate #Drug development #Drug discovery #Market reporting

Thirteen potential blockbuster drugs to watch in 2024

Thirteen new-to-market therapeutics and drugs poised to launch in 2024 will achieve ‘blockbuster’ status by 2029 or deliver game-changing benefits to patients. They include therapeutics for conditions including breast cancer, haemophilia A, sickle cell disease, Crohn’s disease, ulcerative colitis, respiratory syncytial virus (RSV) and multiple myeloma, among… Read More

#News #Trending News #Trends & Analysis

#Drug development #Drug discovery #Life science #Life sciences #Market reporting #TechBio #UK

‘Life Sciences Future50’ shines light on UK innovation

PwC has published a new report on the UK life sciences industry ‘The Life Sciences Future50’, highlighting companies that illustrate world-class science and innovation, including 32 in the therapeutics space. According to the report, the life science industry represents a £43.4 ($52.7) billion annual contribution to… Read More

#News #Trending News #Trends & Analysis

#Artificial intelligence (AI) #BioIndustry Association #Machine learning #TechBio #UK

Five UK TechBio companies driving the AI revolution

The UK TechBio sector is thriving, according to a new report, with a growing number of companies pioneering ground-breaking products and services. A BioIndustry Association (BIA) report lists the widespread adoption of artificial intelligence (AI) and machine learning (ML), the advancement of gene editing technologies, the… Read More

#News #Trends & Analysis

#Carbon emissions #Environmental impact #Green lab movement #Interview #Lab technology #Sustain

The considerations for building sustainable labs in pharma

Listen to this article on the DDW Podcast: DDW Editor Reece Armstrong speaks to Will Fogden, UK Development Manager, Kadans Science Partner, about sustainable efforts in pharma and the considerations industry needs to take into account when developing sustainable buildings. RA: We’ve seen large-scale sustainability… Read More

#Exclusive Content #Trends & Analysis

AI brain
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug discovery #Pharmaceutical industry

Pharma must embrace an AI future says new report

Artificial intelligence (AI) technology has the potential to revolutionise drug discovery and pharma companies need to make plans for a future in which AI is frequently utilised in research, says ResearchAndMarkets.com. However, the change AI will bring about in drug discovery will take some time, according… Read More

#News #Trends & Analysis

EU and US flags
#Advanced Therapies #Cell and gene therapy #EMA #FDA #Regulatory

Overcoming diverging regulatory expectations to bring CGTs to market

Lung-I Cheng, Vice President and Head of Cell & Gene Therapy Service Line at AmerisourceBergen, and Cori Gorman, Senior Director of CMC and Regulatory Affairs at Biopharma Excellence, offer advice on navigating the different and sometimes contradictory regulatory requirements in the US and EU. Over the… Read More

#Exclusive Content #Regulatory #Trends & Analysis